Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LP-261 是一种新型的微管蛋白靶向抗癌剂,可与微管蛋白上的秋水仙碱位点结合,诱导 G2/M 期阻滞,其EC50为 3.2 μM。它可抑制人非小细胞肺癌的生长,可用于癌症研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 282 | 现货 | ||
2 mg | ¥ 416 | 现货 | ||
5 mg | ¥ 698 | 现货 | ||
10 mg | ¥ 1,180 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,590 | 现货 | ||
100 mg | ¥ 5,190 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 789 | 现货 |
产品描述 | LP-261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2/M arrest. |
靶点活性 | Tubulin polymerization:3.2 μM (EC50) |
体外活性 | LP-261 was tested as a single agent in colon adenocarcinoma (SW620) and prostate cancer (LNCaP and PC3) xenografts, evaluating several different dosing schedules. LP-261 was also used in combination with bevacizumab in the SW620 xenograft model. LP-261 also exhibited high oral bioavailability and apparent lack of efflux by intestinal transporters such as ABCB1. LP-261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft model and shown to be schedule dependent. Excellent inhibition of tumor growth in the SW620 model was observed, comparable with paclitaxel[1]. |
体内活性 | LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model[2]. |
分子量 | 421.47 |
分子式 | C22H19N3O4S |
CAS No. | 915412-67-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22 mg/ml (52.20 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3726 mL | 11.8632 mL | 23.7265 mL | 59.3162 mL |
5 mM | 0.4745 mL | 2.3726 mL | 4.7453 mL | 11.8632 mL | |
10 mM | 0.2373 mL | 1.1863 mL | 2.3726 mL | 5.9316 mL | |
20 mM | 0.1186 mL | 0.5932 mL | 1.1863 mL | 2.9658 mL | |
50 mM | 0.0475 mL | 0.2373 mL | 0.4745 mL | 1.1863 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LP-261 915412-67-8 Cytoskeletal Signaling Microtubule Associated NCI-H522 tubulin polymerization tumor SW-620 BXPC-3 H522 anti-mitotic LP261 inhibit LP 261 MCF-7 Inhibitor Microtubule/Tubulin cancer Jurkat inhibitor